Fintel reports that on May 26, 2023, HC Wainwright & Co. reiterated coverage of Gracell Biotechnologies Inc – ADR (NASDAQ:GRCL) with a Buy recommendation.
Analyst Price Forecast Suggests 357.96% Upside
As of May 11, 2023, the average one-year price target for Gracell Biotechnologies Inc – ADR is 12.82. The forecasts range from a low of 7.07 to a high of $21.00. The average price target represents an increase of 357.96% from its latest reported closing price of 2.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gracell Biotechnologies Inc – ADR is 0MM, a decrease of �%. The projected annual non-GAAP EPS is -0.59.
What is the Fund Sentiment?
There are 51 funds or institutions reporting positions in Gracell Biotechnologies Inc – ADR. This is an increase of 1 owner(s) or 2.00% in the last quarter. Average portfolio weight of all funds dedicated to GRCL is 0.09%, a decrease of 0.82%. Total shares owned by institutions increased in the last three months by 44.19% to 31,664K shares.
What are Other Shareholders Doing?
Temasek Holdings holds 9,902K shares representing 14.62% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 9,498K shares representing 14.03% ownership of the company. In it’s prior filing, the firm reported owning 7,885K shares, representing an increase of 16.98%. The firm decreased its portfolio allocation in GRCL by 0.46% over the last quarter.
Great Point Partners holds 3,153K shares representing 4.66% ownership of the company. In it’s prior filing, the firm reported owning 1,962K shares, representing an increase of 37.76%. The firm increased its portfolio allocation in GRCL by 30.16% over the last quarter.
Sphera Funds Management holds 2,361K shares representing 3.49% ownership of the company. In it’s prior filing, the firm reported owning 0K shares, representing an increase of 100.00%.
Vivo Capital holds 1,464K shares representing 2.16% ownership of the company. In it’s prior filing, the firm reported owning 961K shares, representing an increase of 34.33%. The firm decreased its portfolio allocation in GRCL by 25.78% over the last quarter.
Gracell Biotechnologies Background Information
(This description is provided by the company.)
Gracell Biotechnologies Inc. (
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
